Developing targeted gene delivery using engineered viral vectors
Viral vector technology for cell type specific gene delivery
This study is working on a new way to make gene therapy better by using specially designed viruses that can deliver helpful genes directly to cancer cells while avoiding healthy ones, making treatment safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11030221 on NIH RePORTER |
What this research studies
This research focuses on improving gene therapy by creating viral vectors that can specifically deliver genes to targeted cell types, such as cancer cells, while minimizing effects on healthy cells. The approach involves genetically engineering adeno-associated viruses (AAV) to attach monoclonal antibodies that guide the virus to specific receptors on the desired cells. By enhancing the efficiency and specificity of these viral vectors, the research aims to make gene therapy safer and more effective for patients. The project will also explore new engineering strategies and utilize machine learning to optimize the design of these vectors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer or other diseases that could benefit from targeted gene therapy.
Not a fit: Patients with conditions that do not involve specific cell types or those who are not candidates for gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer gene therapies for various diseases, particularly cancers.
How similar studies have performed: Previous research has shown promise in using engineered viral vectors for targeted gene delivery, indicating that this approach has potential for success.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Schmidt, Daniel — University of Minnesota
- Study coordinator: Schmidt, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.